EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion

Xin Wei, Linlin Zhao, Fang Yang, Yajing Yang, Huixiang Zhang, Kaixin Du, Xinxin Tian, Ruihua Fan, Guangxu Si, Kailun Wang, Yulu Li, Zhizhong Wei und 2 weitere

Molecular Therapy · 2024-11 · 32 (11) · 4075-4094

DOI: 10.1016/j.ymthe.2024.09.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024-11. Verfasst von Xin Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Beijing Normal University, Beijing 100875, China; National Institute of Biological Sciences, 7 Science Park Road, Beijing 10…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, T-Lymphocytes, Regulatory, Interleukin-2 Receptor alpha Subunit, Receptors, Immunologic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Municipal Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intratumoral regulatory T cells (Tregs) express high levels of CD25 and TIGIT, which are also recognized as markers of effector T cell (Teff) activation. Targeting these molecules each alone with monoclonal antibodies (mAbs) poses a risk of concurrently depleting both Teffs and peripheral Tregs, thereby compromising the effectiveness and selectivity of intratumoral Treg depletion. Here, leveraging the increased abundance of CD25+ TIGIT+ double-positive Tregs in the solid tumor microenvironment (but not in peripheral tissues), we explore the feasibility of using a CD25×TIGIT bispecific antibody (bsAb) to selectively deplete intratumoral Tregs. We initially constructed a bsAb co-targeting mouse CD25 and TIGIT, NSWm7210, and found that NSWm7210 conferred enhanced intratumoral Treg depletion, Teff activation, and tumor suppression as compared to the parental monotherapies in mouse models. We subsequently constructed a bsAb co-targeting human CD25 and TIGIT (NSWh7216), which preferentially eliminated CD25+ TIGIT+ double-positive cells over single-positive cells in vitro. NSWh7216 exhibited enhanced anti-tumor activity without toxicity of peripheral Tregs in CD25 humanized mice compared to the parental monotherapies. Our study illustrates the use of CD25×TIGIT bsAbs as effective agents against solid tumors based on selective depletion of intratumoral Tregs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificT-Lymphocytes, RegulatoryInterleukin-2 Receptor alpha SubunitReceptors, ImmunologicAnimalsMiceHumansCell Line, TumorLymphocyte DepletionTumor MicroenvironmentXenograft Model Antitumor AssaysDisease Models, AnimalFemaleNeoplasmsLymphocyte Activation

Stichwörter der Autor:innen

CD25TIGITTreg depletionbispecific antibodybsAbintratumoral regulatory T cells

Substanzen

Antibodies, BispecificInterleukin-2 Receptor alpha SubunitReceptors, ImmunologicTIGIT protein, human

Autor:innen und Institutionen

  • School of Life Sciences, Beijing Normal University, Beijing 100875, China; National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China.
  • National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China.
  • National Institute of Biological Sciences, 7 Science Park Road, Beijing 102206, China; Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing 102206, China. Electronic address: suijian…

Förderung

  • Beijing Municipal Science and Technology Commission

Zitieren

APA

Wei, X., Zhao, L., Yang, F., Yang, Y., Zhang, H., Du, K., Tian, X., Fan, R., Si, G., Wang, K., Li, Y., Wei, Z., He, M., & Sui, J. (2024). A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion. Molecular Therapy, 32(11), 4075-4094. https://doi.org/10.1016/j.ymthe.2024.09.010

Vancouver

Wei X, Zhao L, Yang F, Yang Y, Zhang H, Du K, et al. A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion. Molecular Therapy. 2024;32(11):4075-4094. doi:10.1016/j.ymthe.2024.09.010

BibTeX
@article{Wei2024,
  author = {Wei, Xin and Zhao, Linlin and Yang, Fang and Yang, Yajing and Zhang, Huixiang and Du, Kaixin and Tian, Xinxin and Fan, Ruihua and Si, Guangxu and Wang, Kailun and Li, Yulu and Wei, Zhizhong and He, Miaomiao and Sui, Jianhua},
  title = {A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion},
  journal = {Molecular Therapy},
  year = {2024},
  volume = {32},
  number = {11},
  pages = {4075--4094},
  doi = {10.1016/j.ymthe.2024.09.010}
}
Kostenlos starten →